Erythropoietin reduces the development of experimental inflammatory bowel disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 3, 2004, Pages 1272-1280

  Cuzzocrea, Salvatore ^a   Mazzon, Emanuela ^a   Di Paola, Rosanna ^a   Patel, Nimesh S A ^b   Genovese, Tiziana ^a   Muià, Carmelo ^a   De Sarro, Angelina ^a   Thiemermann, Christoph ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; DINITROBENZENESULFONIC ACID; ERYTHROPOIETIN; INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; NITROBENZENE DERIVATIVE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON INJURY; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; ENTERITIS; ENZYME ACTIVITY; ERYTHROID PRECURSOR CELL; EXPERIMENTAL MODEL; HISTOPATHOLOGY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT INDICATION; WEIGHT REDUCTION;

ANIMALS; BENZENESULFONATES; COLITIS; ERYTHROPOIETIN, RECOMBINANT; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; INTESTINAL MUCOSA; MALE; MICE; NEUTROPHIL INFILTRATION; PEROXIDASE; POLY ADENOSINE DIPHOSPHATE RIBOSE; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 10044264303     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.073197     Document Type: Article

References (44)

1. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, and Ghezzi P (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952:128-134.
2. Aiko S and Grisham MB (1995) Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterology 109:142-150.
3. Barnes PJ and Karin M (1997) Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071.
4. Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, and Moncada S (1993) Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 341:338-340.
5. Carty E, De Brabander M, Feakins RM, and Rampton DS (2000) Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 46:487-492.
6. Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Pennington S, Vale L, Wallace S, and MacLeod A (2001) Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev CD003266.
7. Cuzzocrea S, Mazzon E, Dugo L, Caputi AP, Riley DP, and Salvemini D (2001) Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. Eur J Pharmacol 432:79-89.
8. Diaz-Granados N, Howe K, Lu J, and McKay DM (2000) Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156:2169-2177.
9. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205.
10. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, and McEver RP (1990) Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature (Lond) 343:757-760.
11. Grisham MB (1994) Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859-861.
12. Hirayama A, Nagase S, Gotoh M, Ueda A, Ishizu T, Yoh K, Aoyagi K, Terao J, and Koyama A (2002) Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia. Free Radic Res 36:1155-1161.
13. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, and Kuck KH (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64:326-333.
14. Jelkmann W (1992) Erythropoietin: structure, control of production, and function. Physiol Rev 72:449-489.
15. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, and Rosenbaum DM (2002) Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 99:10659-10664.
16. Kitahora T, Suzuki K, Asakura H, Yoshida T, Suematsu M, Watanabe M, Aiso S, and Tsuchiya M (1988) Active oxygen species generated by monocytes and polymorphonuclear cells in patients in Crohn's disease. Dig Dis Sci 33:951-955.
17. Koizumi M, King N, Lobb R, Benjamin C, and Podolsky DK (1992) Expression of vascular adhesion molecules in inflammatory bowel. Gastroenterology 103:840-847.
18. Makis AC, Chaliasos N, Hatzimichael EC, and Bourantas KL (2001) Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient. Ann Hematol 80:492-495.
19. Masuda S, Nagao M, and Sasaki R (1999) Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 70:1-6.
20. Mazzon E, Puzzolo D, Caputi AP, and Cuzzocrea S (2002) Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. Mol Med 8:353-366.
21. Middleton SJ, Shorthouse M, and Hunter JO (1993) Increased nitric oxide synthesis in ulcerative colitis. Lancet 341:465-466.
22. Miller MJ, Thompson JH, Zhang XJ, Sadowska-Krowicka H, Kakkis JL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS, et al. (1995) Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 109:1475-1483.
23. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, and Wallace JL (1989) Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803.
24. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, and Noguchi CT (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275:39754-39761.
25. Papadakis KA and Targan SR (2000) Tumor necrosis factor: biology andtherapeutic inhibitors. Gastroenterology 119:1148-1157.
26. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Investig 112:999-1007.
27. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429.
28. Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, and Podolsky DK (1993) Peroxynitrite-induced rat colitis-a new model of colonic inflammation. Gastroenterology 105:1681-1688.
29. Rey-Ladino JA, Huber M, Liu L, Damen JE, Krystal G, and Takei F (1999) The SH2-containing inositol-5′-phosphatase enhances LFA-1-mediated cell adhesion and defines two signaling pathways for LFA-1 activation. J Immunol 162:5792-5799.
30. Sandborn WJ and Hanauer SB (1999) Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 2:119-133.
31. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, et al. (2003) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 14:2115-2124.
32. Shiratora Y, Aoki S, Takada H, Kiriyama H, Ohto K, Hai K, Teraoka H, Matano S, Matsumoto K, and Kamii K (1993) Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestion 44:163-171.
33. Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, and Stenson WF (1996) Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111:871-885.
34. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, and Caputi AP (1999) Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 127:482-488.
35. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, and Kamm MA (1997) Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349:521-524.
36. Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, and Asou H (2002) Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 44:391-403.
37. Szabó C and Dawson VL (1998) Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19:287-298.
38. Wald MR, Borda ES, and Sterin-Borda L (1996) Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 167:461-468.
39. Wallace JL and Keenan CM (1990) An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 258:G527-G534.
40. Wallace JL, Le T, Carter L, Appleyard CB, and Beck PL (1995) Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Toxicol Methods 33:237-239.
41. Wu H, Lee SH, Gao J, Liu X, and Iruela-Arispe ML (1999) Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126:3597-3605.
42. Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B, Lin CS, Nikodem VM, Hempstead B, Flanders KC, et al. (2002) Erythropoietin receptor signalling is required for normal brain development. Development 129:505-516.
43. Zingarelli B, Szabó C, and Salzman AL (1999a) Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 116:335-345.
44. Zingarelli B, Szabó C, and Salzman AL (1999b) Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 45:199-209.